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ABSTRACT  
A new simple, accurate, precise and reproducible RP-HPLC method has been developed for the simultaneous 
estimation of Saxagliptin and Metformin in bulk drug form using C18 column (Phenomenex, 250 x 4.6 mm, 5 μm) in 
isocratic mode. The mobile phase consisted of 0.02M Potassium dihydrogen phosphate (KH2PO4), Acetonitrile, 
Methanol in the ratio of 50:25:25 (v/v/v) at pH 4.3. The detection wavelength was carried out at 240 nm. The 
method was linear over the concentration range for Saxagliptin 10-50μg/ml and for Metformin 5-25 μg/ml. The 
recoveries of Saxagliptin and Metformin were found to be 100.48and 101.1% respectively. The validation of method 
was carried out utilizing ICH-guidelines. The described HPLC method was successfully employed for the analysis 
of pharmaceutical formulations containing combined dosage form. 
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INTRODUCTION  
Saxagliptin (SXG) is chemically (1S, 3S, 5S)-2-[(2S)-2-Amino-2-(3 hydroxytricyclo [3.3.1.13, 7] dec-1-yl) acetyl]-
2-azabicyclo [3.1.0] hexane-3-carbonitrile previously identified as BMS-477118.This is new oral hypoglycemic 
agent of the new dipeptidyl peptidase- 4 (DPP-4) inhibitor class of drugs. The empirical formula is C18H25N3O2, H2O 















Fig 1 Structure of Saxigliptin (A) and Metformin (B) 
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Saxagliptin recently approved for the treatment of type-2 diabetes mellitus. It has been used in conjunction with 
exercise and diet to improve glycaemic control in patients with type 2 diabetes and is to be used with metformin, a 
sulphonylurea or pioglitazone when blood sugar levels are not adequately controlled by one of these agents alone 6-
12. Literature survey reveals that the drug can be estimated only by LC-MS/MS13, Spectrophotometric method14 have 
been reported. 
Metformin Hydrochloride(MTF) (C4H11N5.HCl) is 1, 1-dimethylbiguanidine monohydrochloride (Fig 1), is an anti-
diabetic drug from the biguanide class of oral hypoglycaemic agents, given orally in the treatment of non –insulin-
dependent diabetes mellitus15 .Major action of metformin HCl  in increasing glucose transport across the cell 
membrane in skeletal muscle16-17 . Several analytical methods based on UV 18-20, Spectroflourimetry21, RP-HPLC22-
30, HPTLC 31and LC-MS/MS32 was reported for the determination of metformin. Although literature survey reveals 
that various methods were reported for Saxagliptin and Metformin   both for single estimation and in combination 
with others drugs, but no estimation method has been reported for the analysis of these drugs in combination. 
EXPERIMENTAL 
Apparatus 
The liquid chromatographic system consists of shimadzu 20 AT with UV-VIS detector, binary pump and rheodyne   
injector valve with 20 μl fixed loop. The analytes were monitored at 240 nm. Chromatographic analysis was 
performed on Phenomenex C18 column having 250 mm× 4.6 mm i.d. and 5 μm particle size. Chramotagram were 
automatically obtained by spinchrome system software.  
Reagents and Materials 
All chemicals and reagents were used of AR grade. Authentic of SXG and MTF were obtained as gift samples from 
Astra Zeneca Pharma India Ltd. 
Selection of detection wavelength 
 Solutions of drug were scanned over the range of 200-400 nm. It was observed that both the drugs showed 
considerable absorbance at 274 nm for SXG and 231nm for MTF .the Isobestic point of both drugs was found to be 
240nm.( Fig. 2 ) 
 
Fig 2 Isobestic point of Saxagliptin and Metformin 
 
Chromatographic Conditions 
The Phenomnex C18 column (250 x 4.6mm, 5µm) equilibrated with mobile phase 0.02M Potassium dihydrogen 
phosphate (KH2PO4), Acetonitrile, Methanol in the ratio of 50:25:25 (v/v/v) at pH 4.3. The flow rate was maintained 
at 1 ml/min, detection wavelength 240 nm, and the injection volume was 20 μl and run time was kept 12 min. 
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Preparation of standard solution 
SXG and MTF were weighed (100 mg each) and transferred to two separate 100ml volumetric flasks and dissolved 
in 50 ml of HPLC grade water and make up the volume up to the mark with water  and the final concentration of  
solution containing 1000 µg/ml of SXG and MTF.  
Preparation of working standard 
Aliquot from the stock solutions of SXG and MTF were appropriately diluted with distilled water to obtain working 
standard of SXG and MTF. 
METHOD DEVELOPMENT 
Lots of mobile phase and there different proportions were tried and finally was selected as 0.02M Potassium 
dihydrogen phosphate (KH2PO4), Acetonitrile, Methanol in the ratio of 50:25:25 (v/v/v) at pH 4.3 appropriate 
mobile phase which gave good resolution and acceptable system suitability parameters. The chromatogram of 
working standard solution is shown in fig 3.  
 
Fig 3 HPLC chromatogram of Saxagliptin and Metformin. 
 
Linearity 
Accurately measured volumes of working standard solution of SXG and MTF were transferred into a series of 10 ml 
volumetric flasks and diluted appropriately with water. 20μl of each solution was injected at same chromatographic 
conditions. Calibration curves were obtained by plotting the peak area versus concentration of drug. Regression 
equations were calculated. The method was found linear over a concentration range 10-50µg/mL of SXG and 5-25 
µg/mL of MTF. (Fig. 4, 5) 
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Fig. 4 Calibration curve of Saxagliptine 
 
Fig. 5 Calibration curve of Metformin 
Precision  
The repeatability studies were carried out by estimating response of SXG (20 µg/mL) and MTF (10µg/mL) five 
times .The intra-day and inter-day precision studies were carried out by estimating the corresponding responses five 
times on interday and intraday for three different concentrations of SXG (10, 30, 50 µg/ml) and MTF (10, 15, 20 
µg/ml) .It is expressed as the percentage coefficient of variation (% CV) which is calculated as per the following 
expression. 
% CV = (standard deviation / mean) x 100. 
Accuracy  
Recovery assessment was obtained by using standard addition technique which was by adding known quantities of 
pure standards at three different levels in 80%, 100% and 120% to the pre analysed sample formulation. From the 
amount of drug found, amount of drug recovered and percentage recovery were calculated which sense to 
conformation that the proposed method was accurate. 
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Table 1 Recovery study 
S. No. Saxagliptin Metformin 
Recovery Level  80 100 120 80 100 120 
Amount present 20 20 20 10 10 10 
Amount added 16 20 24 8 10 12 
Amount recovered 36.23 40.12 44.23 18.4 19.87 22.32 
%Recovery 100.6 100.3 100.5 102.2 99.35 101.45 
Mean % Recovery 100.48 101.08 
 
Detection Limit and Quantitation Limit 
The detection limits were found to be 1.91µg/ml and 0.40µg/ml for SXG and MFT respectively. The quantitation 
limits were found to be 5.78µg/ml and 1.22µg/ml for Saxagliptin SXG and MFT respectively. These values indicate 
that the method is sensitive.  
 
Specificity 
The method was determined as specific by comparing test results obtained from analyses of sample solution 
containing placebo ingredients with that of test results those obtained from analyses of standard solution. 
RESULTS AND DISCUSSION 
The present work done on this combination comprises a simple, precise and accurate method by reverse phase high 
performance liquid chromatography.  An attempt has been made to estimate SXG and MTF by RP-HPLC. 
Calibration curve depicting the linearity and range for SXG and MTF were determined from mixed standards and 
were found to be of the order10-50 µg /ml of SXG and 5-25 µg /ml of MTF. The retention times 4.85 minutes for 
MTF and 7.43 minutes for SXG.  The results obtained from HPLC method were reproducible and encouraging. The 
values percentage deviation was within limit (>2%) and recovery close to 100% indicating reproducibility and 
accuracy of method. 
CONCLUSION  
Proposed study describes method for the estimation of SXG and MTF combination in mixture. The method was 
validated and found to be simple, sensitive, accurate and precise as per ICH guidelines .The method was 
successfully used for determination of drugs in their pharmaceutical formulation. 
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Table 2: Analytical parameters  
S.NO. PARAMETERS Saxagliptin Metformine 
1 Limit of linearity (µg/ml) 10-50 5-25 
2 Regression equation y = 432.7x-326.2 y = 614.1x -88 
3 Slope 432.7 614.1 
4 Intercept 326.2 88 
5 Correlation coefficient (r2) 0.999 0.999 
6 Retention time (min)  4.85 7.43 
7 Detection limit (μg/ml)  1.91 0.40 
8 Quantitation limit (μg/ml)  5.78 1.22 
9 Accuracy (%)  100.48 101.01 
10 Precision ( % CV )  
Repeatibility 
Intra-day precision (n=3)  
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